These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 17927285

  • 1. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
    Yang LP, Keam SJ, Keating GM.
    Drugs; 2007; 67(15):2211-30. PubMed ID: 17927285
    [Abstract] [Full Text] [Related]

  • 2. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
    Shirley M, Plosker GL.
    Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862
    [Abstract] [Full Text] [Related]

  • 3. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
    Cappellini MD, Taher A.
    Expert Opin Pharmacother; 2008 Sep; 9(13):2391-402. PubMed ID: 18710363
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Pharmacoeconomics; 2007 Sep; 25(4):329-42. PubMed ID: 17402805
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Current status of iron overload and chelation with deferasirox.
    Choudhry VP, Naithani R.
    Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
    [Abstract] [Full Text] [Related]

  • 10. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD, Taher A.
    Acta Haematol; 2009 Aug; 122(2-3):165-73. PubMed ID: 19907154
    [Abstract] [Full Text] [Related]

  • 11. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.
    Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [Abstract] [Full Text] [Related]

  • 12. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V, Berdousi H, Gotsis E, Kattamis A.
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [Abstract] [Full Text] [Related]

  • 13. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J, Tolley K, Vieira J, Chandiwana D.
    Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
    [Abstract] [Full Text] [Related]

  • 14. Deferasirox: pharmacokinetics and clinical experience.
    Galanello R, Campus S, Origa R.
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
    [Abstract] [Full Text] [Related]

  • 15. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
    Shashaty G, Frankewich R, Chakraborti T, Choudary J, Al-Fayoumi S, Kacuba A, Castillo S, Robie-Suh K, Rieves D, Weiss K, Pazdur R.
    Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
    [Abstract] [Full Text] [Related]

  • 16. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
    Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T.
    Br J Haematol; 2011 Aug; 154(3):387-97. PubMed ID: 21592110
    [Abstract] [Full Text] [Related]

  • 17. Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
    Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, Grant FD, Paley C, Shannon M, Neufeld EJ.
    Blood; 2009 Nov 05; 114(19):4009-13. PubMed ID: 19724055
    [Abstract] [Full Text] [Related]

  • 18. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T, Deferasirox in Sickle Cell Investigators.
    Br J Haematol; 2007 Feb 05; 136(3):501-8. PubMed ID: 17233848
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.
    Ann Hematol; 2013 Jan 05; 92(2):211-9. PubMed ID: 23086508
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.